Regulus Therapeutics (RGLS) Tops Q1 EPS by 10c
Tweet
Share
E-mail
Get Alerts RGLS Hot Sheet
Join SI Premium – FREE
Regulus Therapeutics (NASDAQ: RGLS) reported Q1 EPS of ($0.15), $0.10 better than the analyst estimate of ($0.25).
For earnings history and earnings-related data on Regulus Therapeutics (RGLS) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Corning (GLW) files for up to $2B offering of common shares
- JPMorgan cut off lending activity for Situational Awareness - FT
- Northrop Grumman wins two U.S. defense contracts worth $38.7m
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
